PT - JOURNAL ARTICLE AU - George Kirov AU - Emily Baker TI - COVID-19 and mortality risk in patients with psychiatric disorders AID - 10.1101/2021.04.08.21255046 DP - 2021 Jan 01 TA - medRxiv PG - 2021.04.08.21255046 4099 - http://medrxiv.org/content/early/2021/04/13/2021.04.08.21255046.short 4100 - http://medrxiv.org/content/early/2021/04/13/2021.04.08.21255046.full AB - COVID-19 has already caused the deaths of over 2.5 million people worldwide. Patients with certain medical conditions and severe psychiatric disorders are at increased risk of dying from it. However, such people have a reduced life expectancy anyway, raising the question whether COVID-19 incurs a specific risk for such patients for dying, over and above the risk of dying from other causes.We analysed the UK Biobank data of half a million middle-aged participants from the UK. From the start of 2020 up to 24th January 2021, 894 participants had died from COVID-19 and another 4,562 had died from other causes. We demonstrate that the risk of dying from COVID-19 among patients with mental health problems, especially those with dementia, schizophrenia, or bipolar disorder, is increased compared to the risk of dying from other causes. This increase among patients with severe psychiatric disorders cannot be explained solely by the higher rate of diabetes or cardiovascular disorders.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work at Cardiff University was funded by the Medical Research Council (MRC) Centre Grant (MR/L010305/1)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank has approval from the National Research Ethics Service Committee North West: "UK Biobank: a large scale prospecitve epidemiological resource of 500,000 people aged 40-69 from around the UK". Reference 11/NW/0382. Our access to the UK Biobank resource was approved under application number 14421, dated 28.08.2015. Data for COVID-19 research was made available by the Biobank to all registered projects, as detailed on the Biobank website: https://www.ukbiobank.ac.uk/enable-your-research/about-our-data/covid-19-dataAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available via the UK Biobank resourse